Xiang-Lin Tan1, Kalyan K Bhattacharyya, Shamit K Dutta, William R Bamlet, Kari G Rabe, Enfeng Wang, Thomas C Smyrk, Ann L Oberg, Gloria M Petersen, Debabrata Mukhopadhyay. 1. From the *Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN; †Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick; ‡Department of Epidemiology, School of Public Health, Rutgers, The State University of New Jersey, Piscataway, NJ; and §Department of Biochemistry and Molecular Biology, ∥Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, and ¶Division of Anatomic Pathology, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVES: To further elucidate the anticancer mechanisms of metformin against pancreatic cancer, we evaluated the inhibitory effects of metformin on pancreatic tumorigenesis in a genetically engineered mouse model and investigated its possible anti-inflammatory and antiangiogenesis effects. METHODS: Six-week-old LSL-Kras;Trp53 mice (10 per group) were administered once daily intraperitoneally with saline (control) for 1 week or metformin (125 mg/kg) for 1 week (Met_1wk) or 3 weeks (Met_3wk) before tumor initiation. All mice continued with their respective injections for 6 weeks after tumor initiation. Molecular changes were evaluated through quantitative polymerase chain reaction, immunohistochemistry, and Western blotting. RESULTS: At euthanasia, pancreatic tumor volume in the Met_1wk (median, 181.8 mm) and Met_3wk (median, 137.9 mm) groups was significantly lower than those in the control group (median, 481.1 mm; P = 0.001 and 0.0009, respectively). No significant difference was observed between the Met_1wk and Met_3wk groups (P = 0.51). These results were further confirmed using tumor weight and tumor burden measurements. Furthermore, metformin treatment decreased the phosphorylation of nuclear factor κB and signal transducer and activator of transcription 3 as well as the expression of specificity protein 1 transcription factor and several nuclear factor κB-regulated genes. CONCLUSIONS: Metformin may inhibit pancreatic tumorigenesis by modulating multiple molecular targets in inflammatory pathways.
OBJECTIVES: To further elucidate the anticancer mechanisms of metformin against pancreatic cancer, we evaluated the inhibitory effects of metformin on pancreatic tumorigenesis in a genetically engineered mouse model and investigated its possible anti-inflammatory and antiangiogenesis effects. METHODS: Six-week-old LSL-Kras;Trp53mice (10 per group) were administered once daily intraperitoneally with saline (control) for 1 week or metformin (125 mg/kg) for 1 week (Met_1wk) or 3 weeks (Met_3wk) before tumor initiation. All mice continued with their respective injections for 6 weeks after tumor initiation. Molecular changes were evaluated through quantitative polymerase chain reaction, immunohistochemistry, and Western blotting. RESULTS: At euthanasia, pancreatic tumor volume in the Met_1wk (median, 181.8 mm) and Met_3wk (median, 137.9 mm) groups was significantly lower than those in the control group (median, 481.1 mm; P = 0.001 and 0.0009, respectively). No significant difference was observed between the Met_1wk and Met_3wk groups (P = 0.51). These results were further confirmed using tumor weight and tumor burden measurements. Furthermore, metformin treatment decreased the phosphorylation of nuclear factor κB and signal transducer and activator of transcription 3 as well as the expression of specificity protein 1 transcription factor and several nuclear factor κB-regulated genes. CONCLUSIONS:Metformin may inhibit pancreatic tumorigenesis by modulating multiple molecular targets in inflammatory pathways.
Authors: Xin-Sheng Deng; Shuiliang Wang; Anlong Deng; Bolin Liu; Susan M Edgerton; Stuart E Lind; Reema Wahdan-Alaswad; Ann D Thor Journal: Cell Cycle Date: 2012-01-15 Impact factor: 4.534
Authors: Chinthalapally V Rao; Altaf Mohammed; Naveena B Janakiram; Qian Li; Rebekah L Ritchie; Stan Lightfoot; Awasthi Vibhudutta; Vernon E Steele Journal: Neoplasia Date: 2012-09 Impact factor: 5.715
Authors: Bharat B Aggarwal; Gautam Sethi; Kwang Seok Ahn; Santosh K Sandur; Manoj K Pandey; Ajaikumar B Kunnumakkara; Bokyung Sung; Haruyo Ichikawa Journal: Ann N Y Acad Sci Date: 2006-12 Impact factor: 5.691
Authors: Daniel M Rotroff; Sook Wah Yee; Kaixin Zhou; Skylar W Marvel; Hetal S Shah; John R Jack; Tammy M Havener; Monique M Hedderson; Michiaki Kubo; Mark A Herman; He Gao; Josyf C Mychaleckyi; Howard L McLeod; Alessandro Doria; Kathleen M Giacomini; Ewan R Pearson; Michael J Wagner; John B Buse; Alison A Motsinger-Reif Journal: Diabetes Date: 2018-04-12 Impact factor: 9.461
Authors: Yunxia Lu; Luis Alberto García Rodríguez; Linnéa Malgerud; Antonio González-Pérez; Mar Martín-Pérez; Jesper Lagergren; Tomas S Bexelius Journal: Br J Cancer Date: 2015-11-17 Impact factor: 7.640